{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:00:47Z","timestamp":1787032847721,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,13]]},"DOI":"10.7759\/cureus.56094","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:36:17Z","timestamp":1710326177000},"source":"Crossref","is-referenced-by-count":7,"title":["A Comparative Review of Typical and Atypical Optic Neuritis: Advancements in Treatments, Diagnostics, and Prognosis"],"prefix":"10.7759","author":[{"given":"Noah J","family":"Spillers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Luther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norris C","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J","family":"Kidder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor  A","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim  C","family":"Lutfallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa  G","family":"Derouen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Tirumala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000768","article-title":"Optic neuritis","volume":"25","author":"Bennett JL","year":"2019","unstructured":"Bennett JL. Optic neuritis. Continuum (Minneap Minn). 2019, 25:1236-64. 10.1212\/CON.0000000000000768","journal-title":"Continuum (Minneap Minn)"},{"key":"ref2","article-title":"Optic Neuritis","author":"Guier CP","year":"2023","unstructured":"Guier CP, Stokkermans TJ. Optic Neuritis. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_3415_20","article-title":"Approach to optic neuritis: an update","volume":"69","author":"Phuljhele S","year":"2021","unstructured":"Phuljhele S, Kedar S, Saxena R. Approach to optic neuritis: an update. Indian J Ophthalmol. 2021, 69:2266-76. 10.4103\/ijo.IJO_3415_20","journal-title":"Indian J Ophthalmol"},{"key":"ref4","unstructured":"Optic neuritis. Pathophysiology, clinical features, and diagnosis. (2023). Accessed: July 20, 2023: https:\/\/www.uptodate.com\/contents\/optic-neuritis-pathophysiology-clinical-features-and-diagnosis."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis","volume":"326","author":"Beck RW","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM Jr, et al.. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992, 326:581-8. 10.1056\/NEJM199202273260901","journal-title":"N Engl J Med"},{"key":"ref6","unstructured":"Diagnosis and classification of optic neuritis. (2023). Accessed. July 1, 2023: https:\/\/www.clinicalkey.com\/#!\/content\/playContent\/1-s2.0-S1474442222002009?returnurl=https:%2F%2Flinkinghub.elsevier...."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3205\/oc000138","article-title":"Atypical optic neuritis - a case with a new surprise every visit","volume":"10","author":"Kaur K","year":"2020","unstructured":"Kaur K, Gurnani B, Devy N. Atypical optic neuritis - a case with a new surprise every visit. GMS Ophthalmol Cases. 2020, 10:Doc11. 10.3205\/oc000138","journal-title":"GMS Ophthalmol Cases"},{"key":"ref8","unstructured":"Neuromy\u00e9lite optique aigu\u00eb . th\u00e8se pr\u00e9sent\u00e9e \u00e0 la Facult\u00e9 de m\u00e9decine. (1894). Accessed: July 20, 2023: https:\/\/gallica.bnf.fr\/ark:\/12148\/bpt6k9766395j.texteImage#."},{"key":"ref9","unstructured":"Neuromyelitis optica spectrum disorder (NMOSD). Clinical features and diagnosis. (2023). Accessed: July 22, 2023: https:\/\/www.uptodate.com\/contents\/neuromyelitis-optica-spectrum-disorder-nmosd-clinical-features-and-diagnosis."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner J","year":"2010","unstructured":"Sellner J, Boggild M, Clanet M, et al.. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010, 17:1019-32. 10.1111\/j.1468-1331.2010.03066.x","journal-title":"Eur J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"1","author":"Wingerchuk DM","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 1:805-15. 10.1016\/S1474-4422(07)70216-8","journal-title":"Lancet Neurol"},{"key":"ref12","unstructured":"National Multiple Sclerosis Society. (2023). Accessed. July 22, 2023: https:\/\/www.nationalmssociety.org\/What-is-MS\/Related-Conditions\/Neuromyelitis-Optica-(NMO)."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_451_20","article-title":"Atypical optic neuritis: an overview","volume":"69","author":"Sarkar P","year":"2021","unstructured":"Sarkar P, Mehtani A, Gandhi HC, Dubey V, Tembhurde PM, Gupta MK. Atypical optic neuritis: an overview. Indian J Ophthalmol. 2021, 69:27-35. 10.4103\/ijo.IJO_451_20","journal-title":"Indian J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.7.920","article-title":"Optical coherence tomography in neuromyelitis optica","volume":"65","author":"de Seze J","year":"2008","unstructured":"de Seze J, Blanc F, Jeanjean L, et al.. Optical coherence tomography in neuromyelitis optica. Arch Neurol. 2008, 65:920-3. 10.1001\/archneur.65.7.920","journal-title":"Arch Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor KC","year":"2007","unstructured":"O'Connor KC, McLaughlin KA, De Jager PL, et al.. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007, 13:211-7. 10.1038\/nm1488","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O'Connell K","year":"2020","unstructured":"O'Connell K, Hamilton-Shield A, Woodhall M, et al.. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. J Neurol Neurosurg Psychiatry. 2020, 91:1126-8. 10.1136\/jnnp-2020-323158","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: Clinical characteristics, radiologic clues, and Outcome","volume":"195","author":"Chen JJ","year":"2018","unstructured":"Chen JJ, Flanagan EP, Jitprapaikulsan J, et al.. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: Clinical characteristics, radiologic clues, and Outcome. Am J Ophthalmol. 2018, 195:8-15. 10.1016\/j.ajo.2018.07.020","journal-title":"Am J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen JJ","year":"2020","unstructured":"Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 2020, 33:47-54. 10.1097\/WCO.0000000000000766","journal-title":"Curr Opin Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2019.08.001","article-title":"Optic neuritis in the era of biomarkers","volume":"65","author":"Chen JJ","year":"2020","unstructured":"Chen JJ, Pittock SJ, Flanagan EP, Lennon VA, Bhatti MT. Optic neuritis in the era of biomarkers. Surv Ophthalmol. 2020, 65:12-7. 10.1016\/j.survophthal.2019.08.001","journal-title":"Surv Ophthalmol"},{"key":"ref20","unstructured":"Optic Neuritis Imaging. (2023). Accessed. July 20, 2023: https:\/\/emedicine.medscape.com\/article\/383642-overview."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/0971-3026.169462","article-title":"Magnetic resonance imaging of optic nerve","volume":"25","author":"Gala F","year":"2015","unstructured":"Gala F. Magnetic resonance imaging of optic nerve. Indian J Radiol Imaging. 2015, 25:421-38. 10.4103\/0971-3026.169462","journal-title":"Indian J Radiol Imaging"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00187-9","article-title":"Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment","volume":"22","author":"Bennett JL","year":"2023","unstructured":"Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, Newman NJ, Galetta SL. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023, 22:89-100. 10.1016\/S1474-4422(22)00187-9","journal-title":"Lancet Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-015-4114-4","article-title":"The signal intensity ratio of the optic nerve to ipsilateral frontal white matter is of value in the diagnosis of acute optic neuritis","volume":"26","author":"Onodera M","year":"2016","unstructured":"Onodera M, Yama N, Hashimoto M, et al.. The signal intensity ratio of the optic nerve to ipsilateral frontal white matter is of value in the diagnosis of acute optic neuritis. Eur Radiol. 2016, 26:2640-5. 10.1007\/s00330-015-4114-4","journal-title":"Eur Radiol"},{"key":"ref24","unstructured":"Fundus. (2023). Accessed. June 25, 2023: https:\/\/www.aao.org\/eye-health\/anatomy\/fundus."},{"key":"ref25","unstructured":"Optical Coherence Tomography. (2023). Accessed. July 20, 2023: https:\/\/eyewiki.aao.org\/Optical_Coherence_Tomography."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13004","article-title":"Optical coherence tomography in acute optic neuritis: a population-based study","volume":"138","author":"Soelberg K","year":"2018","unstructured":"Soelberg K, Specovius S, Zimmermann HG, et al.. Optical coherence tomography in acute optic neuritis: a population-based study. Acta Neurol Scand. 2018, 138:566-73. 10.1111\/ane.13004","journal-title":"Acta Neurol Scand"},{"key":"ref27","article-title":"Visual Evoked Potential","author":"Baiano C","year":"2023","unstructured":"Baiano C, Zeppieri M. Visual Evoked Potential. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-020-09770-3","article-title":"VEP estimation of visual acuity: a systematic review","volume":"142","author":"Hamilton R","year":"2021","unstructured":"Hamilton R, Bach M, Heinrich SP, Hoffmann MB, Odom JV, McCulloch DL, Thompson DA. VEP estimation of visual acuity: a systematic review. Doc Ophthalmol. 2021, 142:25-74. 10.1007\/s10633-020-09770-3","journal-title":"Doc Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00455","article-title":"Vision and vision-related measures in progressive multiple sclerosis","volume":"10","author":"Backner Y","year":"2019","unstructured":"Backner Y, Petrou P, Glick-Shames H, et al.. Vision and vision-related measures in progressive multiple sclerosis. Front Neurol. 2019, 10:455. 10.3389\/fneur.2019.00455","journal-title":"Front Neurol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2019.06.001","article-title":"Critical review: typical and atypical optic neuritis","volume":"64","author":"Abel A","year":"2019","unstructured":"Abel A, McClelland C, Lee MS. Critical review: typical and atypical optic neuritis. Surv Ophthalmol. 2019, 64:770-9. 10.1016\/j.survophthal.2019.06.001","journal-title":"Surv Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70071-5","article-title":"Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis","volume":"4","author":"Miller D","year":"2005","unstructured":"Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005, 4:281-8. 10.1016\/S1474-4422(05)70071-5","journal-title":"Lancet Neurol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.6.727","article-title":"Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up","volume":"65","author":"The Optic Neuritis Study Group","year":"2008","unstructured":"The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008, 65:727-32. 10.1001\/archneur.65.6.727","journal-title":"Arch Neurol"},{"key":"ref33","article-title":"Multiple Sclerosis","author":"Tafti D","year":"2023","unstructured":"Tafti D, Ehsan M, Xixis KL. Multiple Sclerosis. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S140634","article-title":"The role of microglia in multiple sclerosis","volume":"13","author":"Luo C","year":"2017","unstructured":"Luo C, Jian C, Liao Y, et al.. The role of microglia in multiple sclerosis. Neuropsychiatr Dis Treat. 2017, 13:1661-7. 10.2147\/NDT.S140634","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0184-2","article-title":"The pro-remyelination properties of microglia in the central nervous system","volume":"15","author":"Lloyd AF","year":"2019","unstructured":"Lloyd AF, Miron VE. The pro-remyelination properties of microglia in the central nervous system. Nat Rev Neurol. 2019, 15:447-58. 10.1038\/s41582-019-0184-2","journal-title":"Nat Rev Neurol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00201","article-title":"The role of B cells and antibodies in multiple sSclerosis, neuromyelitis optica, and related disorders","volume":"10","author":"H\u00e4usser-Kinzel S","year":"2019","unstructured":"H\u00e4usser-Kinzel S, Weber MS. The role of B cells and antibodies in multiple sSclerosis, neuromyelitis optica, and related disorders. Front Immunol. 2019, 10:201. 10.3389\/fimmu.2019.00201","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1991.01080120057025","article-title":"The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial","volume":"109","year":"1991","unstructured":"The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991, 109.1673-8. 10.1001\/archopht.1991.01080120057025","journal-title":"Arch Ophthalmol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger R","year":"2020","unstructured":"H\u00f6ftberger R, Guo Y, Flanagan EP, et al.. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020, 139:875-92. 10.1007\/s00401-020-02132-y","journal-title":"Acta Neuropathol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells","volume":"141","author":"Machado-Santos J","year":"2018","unstructured":"Machado-Santos J, Saji E, Tr\u00f6scher AR, et al.. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain. 2018, 141:2066-82. 10.1093\/brain\/awy151","journal-title":"Brain"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1744-4","article-title":"Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients","volume":"134","author":"van Nierop GP","year":"2017","unstructured":"van Nierop GP, van Luijn MM, Michels SS, et al.. Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients. Acta Neuropathol. 2017, 134:383-401. 10.1007\/s00401-017-1744-4","journal-title":"Acta Neuropathol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda S","year":"2019","unstructured":"Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019, 19:169-76. 10.7861\/clinmedicine.19-2-169","journal-title":"Clin Med (Lond)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius S","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, et al.. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016, 13:279. 10.1186\/s12974-016-0717-1","journal-title":"J Neuroinflammation"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius S","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, et al.. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016, 13:280. 10.1186\/s12974-016-0718-0","journal-title":"J Neuroinflammation"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan J","year":"2018","unstructured":"Jitprapaikulsan J, Chen JJ, Flanagan EP, et al.. Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis. Ophthalmology. 2018, 125:1628-37. 10.1016\/j.ophtha.2018.03.041","journal-title":"Ophthalmology"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241226830","article-title":"Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","author":"Bilodeau PA","year":"2024","unstructured":"Bilodeau PA, Vishnevetsky A, Molazadeh N, et al.. Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler J. 2024, 10.1177\/13524585241226830","journal-title":"Mult Scler J"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk DM","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al.. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015, 85:177-89. 10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"ref47","article-title":"Neuromyelitis Optica Spectrum Disorder (NMOSD)","author":"Shumway CL","year":"2023","unstructured":"Shumway CL, Patel BC, De Jesus O. Neuromyelitis Optica Spectrum Disorder (NMOSD). StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01028","article-title":"AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD","volume":"10","author":"Prain K","year":"2019","unstructured":"Prain K, Woodhall M, Vincent A, et al.. AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD. Front Neurol. 2019, 10:1028. 10.3389\/fneur.2019.01028","journal-title":"Front Neurol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"11","author":"Lennon VA","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, et al.. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004, 11:2106-12. 10.1016\/S0140-6736(04)17551-X","journal-title":"Lancet"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.20.11981","article-title":"Direct immunogold labeling of aquaporin-4 in square arrays of astrocyte and ependymocyte plasma membranes in rat brain and spinal cord","volume":"95","author":"Rash JE","year":"1998","unstructured":"Rash JE, Yasumura T, Hudson CS, Agre P, Nielsen S. Direct immunogold labeling of aquaporin-4 in square arrays of astrocyte and ependymocyte plasma membranes in rat brain and spinal cord. Proc Natl Acad Sci U S A. 1998, 95:11981-6. 10.1073\/pnas.95.20.11981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-01-00171.1997","article-title":"Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain","volume":"17","author":"Nielsen S","year":"1997","unstructured":"Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci. 1997, 17:171-80. 10.1523\/JNEUROSCI.17-01-00171.1997","journal-title":"J Neurosci"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3390\/cells8020090","article-title":"Aquaporin-4 water channel in the brain and its implication for health and disease","volume":"8","author":"Mader S","year":"2019","unstructured":"Mader S, Brimberg L. Aquaporin-4 water channel in the brain and its implication for health and disease. Cells. 2019, 8:90. 10.3390\/cells8020090","journal-title":"Cells"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000603","article-title":"Treatment of neuromyelitis optica spectrum disorders","volume":"31","author":"Romeo AR","year":"2019","unstructured":"Romeo AR, Segal BM. Treatment of neuromyelitis optica spectrum disorders. Curr Opin Rheumatol. 2019, 31:250-5. 10.1097\/BOR.0000000000000603","journal-title":"Curr Opin Rheumatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita Y","year":"2017","unstructured":"Takeshita Y, Obermeier B, Cotleur AC, et al.. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017, 4:e311. 10.1212\/NXI.0000000000000311","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson SR","year":"2007","unstructured":"Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, Lennon VA. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007, 69:2221-31. 10.1212\/01.WNL.0000289761.64862.ce","journal-title":"Neurology"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081241","article-title":"Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2","volume":"205","author":"Hinson SR","year":"2008","unstructured":"Hinson SR, Roemer SF, Lucchinetti CF, et al.. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008, 205:2473-81. 10.1084\/jem.20081241","journal-title":"J Exp Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10352-1","article-title":"The changing landscape of optic neuritis: a narrative review","volume":"269","author":"De Lott LB","year":"2022","unstructured":"De Lott LB, Bennett JL, Costello F. The changing landscape of optic neuritis: a narrative review. J Neurol. 2022, 269:111-24. 10.1007\/s00415-020-10352-1","journal-title":"J Neurol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.06.060","article-title":"Natural history of the visual impairment of relapsing neuromyelitis optica","volume":"114","author":"Merle H","year":"2007","unstructured":"Merle H, Olindo S, Bonnan M, Donnio A, Richer R, Smadja D, Cabre P. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology. 2007, 114:810-5. 10.1016\/j.ophtha.2006.06.060","journal-title":"Ophthalmology"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk DM","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999, 53:1107-14. 10.1212\/wnl.53.5.1107","journal-title":"Neurology"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0b013e318205a148","article-title":"Bitemporal visual field defects in ethambutol-induced optic neuropathy","volume":"31","author":"Kho RC","year":"2011","unstructured":"Kho RC, Al-Obailan M, Arnold AC. Bitemporal visual field defects in ethambutol-induced optic neuropathy. J Neuroophthalmol. 2011, 31:121-6. 10.1097\/WNO.0b013e318205a148","journal-title":"J Neuroophthalmol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.4103\/aian.AIAN_339_19","article-title":"Toxic optic neuropathy: A rare but serious side effect of chloramphenicol and ciprofloxacin","volume":"23","author":"Radhakrishnan DM","year":"2020","unstructured":"Radhakrishnan DM, Samanta R, Manchanda R, Kumari S, Shree R, Kumar N. Toxic optic neuropathy: A rare but serious side effect of chloramphenicol and ciprofloxacin. Ann Indian Acad Neurol. 2020, 23:413-5. 10.4103\/aian.AIAN_339_19","journal-title":"Ann Indian Acad Neurol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36976","article-title":"Sertraline-induced optic nerve dysfunction","volume":"15","author":"Abuallut I","year":"2023","unstructured":"Abuallut I, Alqassim AY, Ayyashi R. Sertraline-induced optic nerve dysfunction. Cureus. 2023, 15:e36976. 10.7759\/cureus.36976","journal-title":"Cureus"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti E","year":"2021","unstructured":"Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation. 2021, 18:208. 10.1186\/s12974-021-02249-1","journal-title":"J Neuroinflammation"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1002\/jca.1010","article-title":"Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system","volume":"16","author":"Weinshenker BG","year":"2001","unstructured":"Weinshenker BG. Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. J Clin Apher. 2001, 16:39-42. 10.1002\/jca.1010","journal-title":"J Clin Apher"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9796-7","article-title":"Neuromyelitis optica: potential roles for intravenous immunoglobulin","volume":"33","author":"Wingerchuk DM","year":"2013","unstructured":"Wingerchuk DM. Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol. 2013, 33:33-7. 10.1007\/s10875-012-9796-7","journal-title":"J Clin Immunol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.103019","article-title":"Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis","volume":"21","author":"Morales-Ruiz V","year":"2022","unstructured":"Morales-Ruiz V, Ju\u00e1rez-Vaquera VH, Rosetti-Sciutto M, S\u00e1nchez-Mu\u00f1oz F, Adalid-Peralta L. Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis. Autoimmun Rev. 2022, 21:103019. 10.1016\/j.autrev.2021.103019","journal-title":"Autoimmun Rev"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter I","year":"2018","unstructured":"Kleiter I, Gahlen A, Borisow N, et al.. Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018, 5:e504. 10.1212\/NXI.0000000000000504","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref68","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P1.2-075","article-title":"Neuromyelitis optica spectrum disorders: the evaluation of 66 patients followed by Istanbul Bilim University, Department of Neurology (P1.2-075)","volume":"92","author":"Altunrende B","year":"2019","unstructured":"Altunrende B, Nalbantoglu M, Y\u00fccel U, Demir GA. Neuromyelitis optica spectrum disorders: the evaluation of 66 patients followed by Istanbul Bilim University, Department of Neurology (P1.2-075). Neurology. 2019, 92:15.","journal-title":"Neurology"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001430.pub4","article-title":"Corticosteroids for treating optic neuritis","author":"Gal RL","year":"2015","unstructured":"Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2015, CD001430. 10.1002\/14651858.CD001430.pub4","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/228220-a-comparative-review-of-typical-and-atypical-optic-neuritis-advancements-in-treatments-diagnostics-and-prognosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:36:32Z","timestamp":1710326192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/228220-a-comparative-review-of-typical-and-atypical-optic-neuritis-advancements-in-treatments-diagnostics-and-prognosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":69,"URL":"https:\/\/doi.org\/10.7759\/cureus.56094","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,13]]}}}